# A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

> **NCT07250594** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Advagene Biopharma Co. Ltd.** · enrollment: 126 (estimated)

## Conditions studied

- Eosinophilic Asthma

## Interventions

- **BIOLOGICAL:** AD17002
- **OTHER:** Formulation buffer

## Key facts

- **NCT ID:** NCT07250594
- **Lead sponsor:** Advagene Biopharma Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07250594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07250594, "A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07250594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*